Allogene Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$819.8M
Industry:Biotech
Founded:2018
Lead Investor(s):Perceptive Advisors
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • Allogene Therapeutics's revenue is currently $7M per year.
  • Allogene Therapeutics received $120.0M in venture funding in September 2018.
  • Allogene Therapeutics's revenue per employee is $52841
  • Allogene Therapeutics's total funding is $819.8M.

Employee Data

  • Allogene Therapeutics has 132 Employees.
  • Allogene Therapeutics grew their employee count by 193% last year.
  • Allogene Therapeutics currently has N/A job openings.

What Is Allogene Therapeutics?

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for off-the-shelf use in patients. This approach eliminates the need to create personalized therapy from a patient's own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy currently in Phase 1 development for the treatment of acute lymphoblastic leukemia (ALL). Through its notable partnerships, Allogene leverages pioneering technology platforms, including TALEN® gene editing technology, to progress its portfolio of immuno-oncology therapies. Allogene, with headquarters in San Francisco, California, is a Two River portfolio company formed with one of the largest Series A financings in biotechnology from an investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer, among others. For more information, please visit www.allogene.com, follow @AllogeneTx on Twitter and LinkedIn.

keywords:N/A

132

Number of Employees

$7M

Revenue (est)

N/A

Current Jobs

193%

Employee Growth %

$819.8M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Mission Bio
$7.4M6944%
Rigel Pharmaceu...
$40.5M2714%
ProTrials Resea...
$25.6M1703%
Advanced Cell D...
$23.9M1668%
CellMax Life
$10M379%$9M
Atreca
$10.7M8117%
Full Spectrum A...
$5.7M395%
Pipette.com/Acc...
N/AN/A
Irvine Scientif...
$29.1M2059%
Talis Biomedica...
$8.1M544%

Allogene Therapeutics News

20-Mar-19 - Financial Survey: Allogene Therapeutics (ALLO) vs. Its Peers

Allogene Therapeutics (NASDAQ: ALLO) is one of 297 public companies in the “Biotechnology” industry, but how does it compare to its peers?

9-Mar-19 - Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2018

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2018 Earnings Conference Call March 8, 2019 8:30 PM ET. Company Participants. Christine

8-Mar-19 - Allogene Therapeutics Reports Fourth Quarter and Full Year 2018

SOUTH SAN FRANCISCO, Calif., March 08, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage

Allogene Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-04-20$411.8MUndisclosedVida VenturesArticle
2018-09-07$120.0MUndisclosedPerceptive AdvisorsArticle

Allogene Therapeutics Executive Hires

DateNameTitleReference
2018-06-05Alison MooreChief Technical OfficerArticle
2018-06-19Eric SchmidtChief Financial OfficerArticle
2018-08-15Susie JunChief Development OfficerArticle
2018-08-29David TillettSVP/Head of QualityArticle